BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. There are 1.4 billion people worldwide living with hypertension.1 In the US, approximately 50% of patients living with hypertension who are already taking multiple antihypertensive me.